Navigation Links
Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
Date:5/13/2008

Company Now Has Four Phase 2 Trials Underway

MONTVALE, N.J., May 13 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) has dosed the first patient in a 160-patient Phase 2 study of alagebrium in patients with diastolic heart failure. BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) is a randomized, double-blind, placebo controlled study to assess the effect of six months of oral treatment with 400mg (200mg twice daily) alagebrium versus placebo in patients diagnosed with diastolic heart failure as verified by echocardiography. The trial will ultimately enroll 80 patients per cohort and be conducted in as many as 25 centers in the United States. Investigators intend that at least half of the study subjects will have diabetes mellitus. The primary efficacy measure of the study is improvement of exercise tolerance as assessed by the six-minute walk test, an accepted regulatory endpoint. In addition, there will be a number of secondary and tertiary measurements including the effect on carboxymethyllysine (CML), a biomarker of A.G.E., against which Synvista has developed a proprietary monoclonal antibody, 4G9, which can be developed into an in-vitro diagnostic test.

"This is a very important study for alagebrium. By looking at the results of the BREAK study along with our BENEFICIAL study in systolic heart failure, we will have a better understanding of the role of A.G.E.s in heart failure," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on what we learn from these studies, there is immense potential to expand the scope of treatment modal
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
3. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Synvista Therapeutics to be Featured on Wallst.net
7. Synvista Therapeutics to Present at the BIO InvestorForum 2007
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
10. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., ... novel drugs for diseases of the central nervous system, ... and chief executive officer, will present at the 33 ... presentation will take place at 3:00 p.m. PST on ... in San Francisco, Calif. ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... TARRYTOWN, N.Y., Oct. 15 EpiCept Corporation,(Nasdaq and ... John Drewe,Senior Director of Lead Discovery, will be ... Targets at the Hotel Del Coronado in San ... describe the advances into pre-clinical,testing of drug discovery ...
... Mich., Oct. 15 In only a few days ... Network has,already received dozens of inquiries from around the ... The Michigan Virtual BioPharma Company, LLC and the ... to be launched at an,exhibit at 5:00 p.m. on ...
... Meeting is the premier,meeting in the science and practice ... treatments, and the results from pilot and,multicenter studies. ... liver disease,and the diseases strike disproportionately among certain populations ... treatments,for both hepatitis B and C, whereas liver cancer ...
Cached Biology Technology:EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 2EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 3EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 4EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference 5Michigan Life Science Network: Virtual Companies Get Global Reception 2
(Date:12/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces it has ... Robbins for the 2015 International CES debut of ... Apollo Robbins will be at the NXT-ID booth ... of his famous theft techniques to visiting media and ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) ... Monitor: North America Perimeter Security Systems Market" report ... The North American perimeter security market ... from 2014 to 2019. Although the U.S. market holds ... is expected to grow at a higher ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... A impairs the function of proteins that are vital ... reported by researchers from the Ruhr-Universitt Bochum and the ... in many plastic products and is suspected of being ... that bisphenol A produces a harmful effect by binding ...
... 2014 /PRNewswire-iReach/ -- Urbanrehab: Physiotherapy and Rehabilitation Specialists, a ... has just announced that they have secured a strategic ... Mark Chern that will allow them to ... . (Photo: http://photos.prnewswire.com/prnh/20140109/MN43520 ) ...
... the speakers for the New & Notable Symposium, which ... in San Francisco, California. The New & Notable ... biophysics. Speakers are nominated by the Society,s membership and ... before the meeting. Over 150 nominations were received this ...
Cached Biology News:Evidence of harmful effect of bisphenol A-based plastics 2Traditional Chinese Medicine in Singapore is Now Available at Urbanrehab Pte Ltd 2Traditional Chinese Medicine in Singapore is Now Available at Urbanrehab Pte Ltd 3Biophysical Society Annual Meeting 2
... For use with suspension ... RiboCap™ uses vacuum filtration or ... culture media. Compatible with ... available in larger package sizes ...
nuclear cap binding protein subunit 1, 80kDa, mRNA...
... Captivate magnetic separator for ... used in conjunction with the ... C-21476) or other magnetic particles ... 96-well microplates. Cell Biology Cell ...
ANTI DEOXY CORTICO...
Biology Products: